#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Feline leukaemia virus ( FeLV ) is a gammaretrovirus that infects domestic cats and closely related wild felids worldwide .
2-1	16-22	Feline	animal|abstract[4]	new|new[4]	appos|coref|appos|coref	2-5[0_4]|3-11|2-5[0_4]|3-11
2-2	23-32	leukaemia	abstract|abstract[4]	new|new[4]	_	_
2-3	33-38	virus	abstract[4]	new[4]	_	_
2-4	39-40	(	_	_	_	_
2-5	41-45	FeLV	abstract	giv	coref	2-8[6_0]
2-6	46-47	)	_	_	_	_
2-7	48-50	is	_	_	_	_
2-8	51-52	a	abstract[6]	giv[6]	coref	3-6[10_6]
2-9	53-68	gammaretrovirus	abstract[6]	giv[6]	_	_
2-10	69-73	that	_	_	_	_
2-11	74-81	infects	_	_	_	_
2-12	82-90	domestic	animal[7]	new[7]	coref	4-9[23_7]
2-13	91-95	cats	animal[7]	new[7]	_	_
2-14	96-99	and	_	_	_	_
2-15	100-107	closely	_	_	_	_
2-16	108-115	related	_	_	_	_
2-17	116-120	wild	animal[8]	new[8]	_	_
2-18	121-127	felids	animal[8]	new[8]	_	_
2-19	128-137	worldwide	_	_	_	_
2-20	138-139	.	_	_	_	_

#Text=Since the first description of the virus in 1964 in feline lymphoma tissue , increasing knowledge has been gained concerning the pathogenesis , diagnosis , and treatment of the infection .
3-1	140-145	Since	_	_	_	_
3-2	146-149	the	abstract[9]	new[9]	_	_
3-3	150-155	first	abstract[9]	new[9]	_	_
3-4	156-167	description	abstract[9]	new[9]	_	_
3-5	168-170	of	abstract[9]	new[9]	_	_
3-6	171-174	the	abstract[9]|abstract[10]	new[9]|giv[10]	coref	4-1[0_10]
3-7	175-180	virus	abstract[9]|abstract[10]	new[9]|giv[10]	_	_
3-8	181-183	in	abstract[9]	new[9]	_	_
3-9	184-188	1964	abstract[9]|time[11]	new[9]|new[11]	_	_
3-10	189-191	in	abstract[9]|time[11]	new[9]|new[11]	_	_
3-11	192-198	feline	abstract[9]|time[11]|abstract|object[14]	new[9]|new[11]|giv|new[14]	_	_
3-12	199-207	lymphoma	abstract[9]|time[11]|abstract|object[14]	new[9]|new[11]|new|new[14]	_	_
3-13	208-214	tissue	abstract[9]|time[11]|object[14]	new[9]|new[11]|new[14]	_	_
3-14	215-216	,	_	_	_	_
3-15	217-227	increasing	abstract[15]	new[15]	_	_
3-16	228-237	knowledge	abstract[15]	new[15]	_	_
3-17	238-241	has	_	_	_	_
3-18	242-246	been	_	_	_	_
3-19	247-253	gained	_	_	_	_
3-20	254-264	concerning	_	_	_	_
3-21	265-268	the	abstract[16]	new[16]	_	_
3-22	269-281	pathogenesis	abstract[16]	new[16]	_	_
3-23	282-283	,	_	_	_	_
3-24	284-293	diagnosis	abstract	new	_	_
3-25	294-295	,	_	_	_	_
3-26	296-299	and	_	_	_	_
3-27	300-309	treatment	abstract[18]	new[18]	_	_
3-28	310-312	of	abstract[18]	new[18]	_	_
3-29	313-316	the	abstract[18]|abstract[19]	new[18]|new[19]	coref	4-1[21_19]
3-30	317-326	infection	abstract[18]|abstract[19]	new[18]|new[19]	_	_
3-31	327-328	.	_	_	_	_

#Text=FeLV infection can lead to fatal diseases in cats with progressive infection .
4-1	329-333	FeLV	object|abstract[21]	giv|giv[21]	coref|coref|coref|coref	4-11[24_21]|5-16|4-11[24_21]|5-16
4-2	334-343	infection	abstract[21]	giv[21]	_	_
4-3	344-347	can	_	_	_	_
4-4	348-352	lead	_	_	_	_
4-5	353-355	to	_	_	_	_
4-6	356-361	fatal	abstract[22]	new[22]	_	_
4-7	362-370	diseases	abstract[22]	new[22]	_	_
4-8	371-373	in	abstract[22]	new[22]	_	_
4-9	374-378	cats	abstract[22]|animal[23]	new[22]|giv[23]	coref	10-15[52_23]
4-10	379-383	with	abstract[22]|animal[23]	new[22]|giv[23]	_	_
4-11	384-395	progressive	abstract[22]|animal[23]|abstract[24]	new[22]|giv[23]|giv[24]	coref	18-6[119_24]
4-12	396-405	infection	abstract[22]|animal[23]|abstract[24]	new[22]|giv[23]|giv[24]	_	_
4-13	406-407	.	_	_	_	_

#Text=Testing and eradication programs and the introduction of effective vaccines led to a decrease in FeLV prevalence in many countries in the last 30 years .
5-1	408-415	Testing	_	_	_	_
5-2	416-419	and	_	_	_	_
5-3	420-431	eradication	abstract|abstract[26]	new|new[26]	_	_
5-4	432-440	programs	abstract[26]	new[26]	_	_
5-5	441-444	and	_	_	_	_
5-6	445-448	the	event[27]	new[27]	_	_
5-7	449-461	introduction	event[27]	new[27]	_	_
5-8	462-464	of	event[27]	new[27]	_	_
5-9	465-474	effective	event[27]|object[28]	new[27]|new[28]	_	_
5-10	475-483	vaccines	event[27]|object[28]	new[27]|new[28]	_	_
5-11	484-487	led	_	_	_	_
5-12	488-490	to	_	_	_	_
5-13	491-492	a	event[29]	new[29]	coref	6-6[34_29]
5-14	493-501	decrease	event[29]	new[29]	_	_
5-15	502-504	in	event[29]	new[29]	_	_
5-16	505-509	FeLV	event[29]|abstract|abstract[31]	new[29]|giv|new[31]	coref|coref|coref|coref	6-10|6-9[36_31]|6-10|6-9[36_31]
5-17	510-520	prevalence	event[29]|abstract[31]	new[29]|new[31]	_	_
5-18	521-523	in	event[29]|abstract[31]	new[29]|new[31]	_	_
5-19	524-528	many	event[29]|abstract[31]|place[32]	new[29]|new[31]|new[32]	coref	7-2[37_32]
5-20	529-538	countries	event[29]|abstract[31]|place[32]	new[29]|new[31]|new[32]	_	_
5-21	539-541	in	event[29]|abstract[31]|place[32]	new[29]|new[31]|new[32]	_	_
5-22	542-545	the	event[29]|abstract[31]|place[32]|time[33]	new[29]|new[31]|new[32]|new[33]	_	_
5-23	546-550	last	event[29]|abstract[31]|place[32]|time[33]	new[29]|new[31]|new[32]|new[33]	_	_
5-24	551-553	30	event[29]|abstract[31]|place[32]|time[33]	new[29]|new[31]|new[32]|new[33]	_	_
5-25	554-559	years	event[29]|abstract[31]|place[32]|time[33]	new[29]|new[31]|new[32]|new[33]	_	_
5-26	560-561	.	_	_	_	_

#Text=However , more recently , the decrease of the FeLV prevalence has stagnated .
6-1	562-569	However	_	_	_	_
6-2	570-571	,	_	_	_	_
6-3	572-576	more	_	_	_	_
6-4	577-585	recently	_	_	_	_
6-5	586-587	,	_	_	_	_
6-6	588-591	the	event[34]	giv[34]	_	_
6-7	592-600	decrease	event[34]	giv[34]	_	_
6-8	601-603	of	event[34]	giv[34]	_	_
6-9	604-607	the	event[34]|abstract[36]	giv[34]|giv[36]	coref	8-11[0_36]
6-10	608-612	FeLV	event[34]|abstract|abstract[36]	giv[34]|giv|giv[36]	coref	7-9
6-11	613-623	prevalence	event[34]|abstract[36]	giv[34]|giv[36]	_	_
6-12	624-627	has	_	_	_	_
6-13	628-637	stagnated	_	_	_	_
6-14	638-639	.	_	_	_	_

#Text=In other countries , such as Denmark , FeLV is rarely detected nowadays .
7-1	640-642	In	_	_	_	_
7-2	643-648	other	place[37]	giv[37]	coref	9-14[48_37]
7-3	649-658	countries	place[37]	giv[37]	_	_
7-4	659-660	,	place[37]	giv[37]	_	_
7-5	661-665	such	place[37]	giv[37]	_	_
7-6	666-668	as	place[37]	giv[37]	_	_
7-7	669-676	Denmark	place[37]|place	giv[37]|new	_	_
7-8	677-678	,	_	_	_	_
7-9	679-683	FeLV	abstract	giv	coref	9-12
7-10	684-686	is	_	_	_	_
7-11	687-693	rarely	_	_	_	_
7-12	694-702	detected	_	_	_	_
7-13	703-711	nowadays	_	_	_	_
7-14	712-713	.	_	_	_	_

#Text=For the USA , Canada , and Australia , large prevalence studies have been published .
8-1	714-717	For	_	_	_	_
8-2	718-721	the	place[40]	new[40]	_	_
8-3	722-725	USA	place[40]	new[40]	_	_
8-4	726-727	,	_	_	_	_
8-5	728-734	Canada	place	new	_	_
8-6	735-736	,	_	_	_	_
8-7	737-740	and	_	_	_	_
8-8	741-750	Australia	place	new	_	_
8-9	751-752	,	_	_	_	_
8-10	753-758	large	event[44]	new[44]	coref	9-5[45_44]
8-11	759-769	prevalence	abstract|event[44]	giv|new[44]	coref	9-9[46_0]
8-12	770-777	studies	event[44]	new[44]	_	_
8-13	778-782	have	_	_	_	_
8-14	783-787	been	_	_	_	_
8-15	788-797	published	_	_	_	_
8-16	798-799	.	_	_	_	_

#Text=There have also been some recent studies on the prevalence of FeLV in single European countries .
9-1	800-805	There	_	_	_	_
9-2	806-810	have	_	_	_	_
9-3	811-815	also	_	_	_	_
9-4	816-820	been	_	_	_	_
9-5	821-825	some	event[45]	giv[45]	_	_
9-6	826-832	recent	event[45]	giv[45]	_	_
9-7	833-840	studies	event[45]	giv[45]	_	_
9-8	841-843	on	event[45]	giv[45]	_	_
9-9	844-847	the	event[45]|abstract[46]	giv[45]|giv[46]	coref	10-10[51_46]
9-10	848-858	prevalence	event[45]|abstract[46]	giv[45]|giv[46]	_	_
9-11	859-861	of	event[45]|abstract[46]	giv[45]|giv[46]	_	_
9-12	862-866	FeLV	event[45]|abstract[46]|abstract	giv[45]|giv[46]|giv	coref	10-12
9-13	867-869	in	event[45]|abstract[46]	giv[45]|giv[46]	_	_
9-14	870-876	single	event[45]|abstract[46]|place[48]	giv[45]|giv[46]|giv[48]	coref	14-10[91_48]
9-15	877-885	European	event[45]|abstract[46]|place[48]	giv[45]|giv[46]|giv[48]	_	_
9-16	886-895	countries	event[45]|abstract[46]|place[48]	giv[45]|giv[46]|giv[48]	_	_
9-17	896-897	.	_	_	_	_

#Text=However , there has been no pan-European study determining the current FeLV prevalence in domestic cats .
10-1	898-905	However	_	_	_	_
10-2	906-907	,	_	_	_	_
10-3	908-913	there	_	_	_	_
10-4	914-917	has	_	_	_	_
10-5	918-922	been	_	_	_	_
10-6	923-925	no	abstract[49]	new[49]	coref	15-4[95_49]
10-7	926-938	pan-European	abstract[49]	new[49]	_	_
10-8	939-944	study	abstract[49]	new[49]	_	_
10-9	945-956	determining	_	_	_	_
10-10	957-960	the	abstract[51]	giv[51]	coref	11-1[54_51]
10-11	961-968	current	abstract[51]	giv[51]	_	_
10-12	969-973	FeLV	abstract|abstract[51]	giv|giv[51]	coref	11-1
10-13	974-984	prevalence	abstract[51]	giv[51]	_	_
10-14	985-987	in	abstract[51]	giv[51]	_	_
10-15	988-996	domestic	abstract[51]|animal[52]	giv[51]|giv[52]	coref	11-16[58_52]
10-16	997-1001	cats	abstract[51]|animal[52]	giv[51]|giv[52]	_	_
10-17	1002-1003	.	_	_	_	_

#Text=FeLV prevalence can vary considerably depending on the composition of the investigated cat population ; feral or stray cats versus privately owned cats , cats in shelters or from breeders , clinically healthy cats or sick cats .
11-1	1004-1008	FeLV	abstract|abstract[54]	giv|giv[54]	coref|coref|coref|coref	12-27|13-9[71_54]|12-27|13-9[71_54]
11-2	1009-1019	prevalence	abstract[54]	giv[54]	_	_
11-3	1020-1023	can	_	_	_	_
11-4	1024-1028	vary	_	_	_	_
11-5	1029-1041	considerably	_	_	_	_
11-6	1042-1051	depending	_	_	_	_
11-7	1052-1054	on	_	_	_	_
11-8	1055-1058	the	abstract[55]	new[55]	_	_
11-9	1059-1070	composition	abstract[55]	new[55]	_	_
11-10	1071-1073	of	abstract[55]	new[55]	_	_
11-11	1074-1077	the	abstract[55]|abstract[57]	new[55]|new[57]	_	_
11-12	1078-1090	investigated	abstract[55]|abstract[57]	new[55]|new[57]	_	_
11-13	1091-1094	cat	abstract[55]|animal|abstract[57]	new[55]|new|new[57]	coref	18-25[126_0]
11-14	1095-1105	population	abstract[55]|abstract[57]	new[55]|new[57]	_	_
11-15	1106-1107	;	_	_	_	_
11-16	1108-1113	feral	animal[58]	giv[58]	coref	11-23[59_58]
11-17	1114-1116	or	animal[58]	giv[58]	_	_
11-18	1117-1122	stray	animal[58]	giv[58]	_	_
11-19	1123-1127	cats	animal[58]	giv[58]	_	_
11-20	1128-1134	versus	_	_	_	_
11-21	1135-1144	privately	_	_	_	_
11-22	1145-1150	owned	_	_	_	_
11-23	1151-1155	cats	animal[59]	giv[59]	coref	12-21[0_59]
11-24	1156-1157	,	animal[59]	giv[59]	_	_
11-25	1158-1162	cats	animal[59]	giv[59]	_	_
11-26	1163-1165	in	animal[59]	giv[59]	_	_
11-27	1166-1174	shelters	animal[59]|place	giv[59]|new	_	_
11-28	1175-1177	or	animal[59]	giv[59]	_	_
11-29	1178-1182	from	animal[59]	giv[59]	_	_
11-30	1183-1191	breeders	animal[59]|person	giv[59]|new	_	_
11-31	1192-1193	,	animal[59]	giv[59]	_	_
11-32	1194-1204	clinically	animal[59]	giv[59]	_	_
11-33	1205-1212	healthy	animal[59]	giv[59]	_	_
11-34	1213-1217	cats	animal[59]	giv[59]	_	_
11-35	1218-1220	or	animal[59]	giv[59]	_	_
11-36	1221-1225	sick	animal[59]	giv[59]	_	_
11-37	1226-1230	cats	animal[59]	giv[59]	_	_
11-38	1231-1232	.	_	_	_	_

#Text=In addition , preselection of the samples has an influence ; e. g. , if samples are obtained only from cats suspected of being infected with FeLV .
12-1	1233-1235	In	_	_	_	_
12-2	1236-1244	addition	_	_	_	_
12-3	1245-1246	,	_	_	_	_
12-4	1247-1259	preselection	abstract[62]	new[62]	_	_
12-5	1260-1262	of	abstract[62]	new[62]	_	_
12-6	1263-1266	the	abstract[62]|object[63]	new[62]|new[63]	coref	12-16[0_63]
12-7	1267-1274	samples	abstract[62]|object[63]	new[62]|new[63]	_	_
12-8	1275-1278	has	_	_	_	_
12-9	1279-1281	an	abstract[64]	new[64]	_	_
12-10	1282-1291	influence	abstract[64]	new[64]	_	_
12-11	1292-1293	;	_	_	_	_
12-12	1294-1296	e.	_	_	_	_
12-13	1297-1299	g.	_	_	_	_
12-14	1300-1301	,	_	_	_	_
12-15	1302-1304	if	_	_	_	_
12-16	1305-1312	samples	object	giv	_	_
12-17	1313-1316	are	_	_	_	_
12-18	1317-1325	obtained	_	_	_	_
12-19	1326-1330	only	_	_	_	_
12-20	1331-1335	from	_	_	_	_
12-21	1336-1340	cats	animal	giv	coref	15-17
12-22	1341-1350	suspected	_	_	_	_
12-23	1351-1353	of	_	_	_	_
12-24	1354-1359	being	_	_	_	_
12-25	1360-1368	infected	_	_	_	_
12-26	1369-1373	with	_	_	_	_
12-27	1374-1378	FeLV	animal	giv	coref	13-9
12-28	1379-1380	.	_	_	_	_

#Text=A recent meta-analysis suggested an indirect relation between FeLV prevalence and the yearly gross domestic product ( GDP ) per capita using purchasing power parity ( PPP ) , i. e. , the total value of all the goods and services produced by a country in a particular year , divided by the number of people living there and corrected for purchasing power using a “ basket of goods ” .
13-1	1381-1382	A	abstract[68]	new[68]	_	_
13-2	1383-1389	recent	abstract[68]	new[68]	_	_
13-3	1390-1403	meta-analysis	abstract[68]	new[68]	_	_
13-4	1404-1413	suggested	_	_	_	_
13-5	1414-1416	an	abstract[69]	new[69]	_	_
13-6	1417-1425	indirect	abstract[69]	new[69]	_	_
13-7	1426-1434	relation	abstract[69]	new[69]	_	_
13-8	1435-1442	between	abstract[69]	new[69]	_	_
13-9	1443-1447	FeLV	abstract[69]|abstract|abstract[71]|abstract[72]	new[69]|giv|giv[71]|new[72]	coref|coref|coref|coref|coref|coref|coref|coref|coref	14-4|14-5[0_71]|19-17[134_72]|14-4|14-5[0_71]|19-17[134_72]|14-4|14-5[0_71]|19-17[134_72]
13-10	1448-1458	prevalence	abstract[69]|abstract[71]|abstract[72]	new[69]|giv[71]|new[72]	_	_
13-11	1459-1462	and	abstract[69]|abstract[72]	new[69]|new[72]	_	_
13-12	1463-1466	the	abstract[69]|abstract[72]|quantity[74]	new[69]|new[72]|new[74]	_	_
13-13	1467-1473	yearly	abstract[69]|abstract[72]|quantity[74]	new[69]|new[72]|new[74]	_	_
13-14	1474-1479	gross	abstract[69]|abstract[72]|person|quantity[74]	new[69]|new[72]|new|new[74]	_	_
13-15	1480-1488	domestic	abstract[69]|abstract[72]|quantity[74]	new[69]|new[72]|new[74]	_	_
13-16	1489-1496	product	abstract[69]|abstract[72]|quantity[74]	new[69]|new[72]|new[74]	_	_
13-17	1497-1498	(	_	_	_	_
13-18	1499-1502	GDP	abstract	new	coref	19-21[135_0]
13-19	1503-1504	)	_	_	_	_
13-20	1505-1508	per	_	_	_	_
13-21	1509-1515	capita	_	_	_	_
13-22	1516-1521	using	_	_	_	_
13-23	1522-1532	purchasing	_	_	_	_
13-24	1533-1538	power	abstract|abstract[77]	new|new[77]	appos|coref|appos|coref	13-27[0_77]|13-63|13-27[0_77]|13-63
13-25	1539-1545	parity	abstract[77]	new[77]	_	_
13-26	1546-1547	(	_	_	_	_
13-27	1548-1551	PPP	abstract	giv	_	_
13-28	1552-1553	)	_	_	_	_
13-29	1554-1555	,	_	_	_	_
13-30	1556-1558	i.	_	_	_	_
13-31	1559-1561	e.	_	_	_	_
13-32	1562-1563	,	_	_	_	_
13-33	1564-1567	the	abstract[79]	new[79]	_	_
13-34	1568-1573	total	abstract[79]	new[79]	_	_
13-35	1574-1579	value	abstract[79]	new[79]	_	_
13-36	1580-1582	of	abstract[79]	new[79]	_	_
13-37	1583-1586	all	abstract[79]|object[80]	new[79]|new[80]	coref	13-69[0_80]
13-38	1587-1590	the	abstract[79]|object[80]	new[79]|new[80]	_	_
13-39	1591-1596	goods	abstract[79]|object[80]	new[79]|new[80]	_	_
13-40	1597-1600	and	abstract[79]	new[79]	_	_
13-41	1601-1609	services	abstract[79]|abstract	new[79]|new	_	_
13-42	1610-1618	produced	_	_	_	_
13-43	1619-1621	by	_	_	_	_
13-44	1622-1623	a	place[82]	new[82]	_	_
13-45	1624-1631	country	place[82]	new[82]	_	_
13-46	1632-1634	in	place[82]	new[82]	_	_
13-47	1635-1636	a	place[82]|time[83]	new[82]|new[83]	_	_
13-48	1637-1647	particular	place[82]|time[83]	new[82]|new[83]	_	_
13-49	1648-1652	year	place[82]|time[83]	new[82]|new[83]	_	_
13-50	1653-1654	,	_	_	_	_
13-51	1655-1662	divided	_	_	_	_
13-52	1663-1665	by	_	_	_	_
13-53	1666-1669	the	quantity[84]	new[84]	_	_
13-54	1670-1676	number	quantity[84]	new[84]	_	_
13-55	1677-1679	of	quantity[84]	new[84]	_	_
13-56	1680-1686	people	quantity[84]	new[84]	_	_
13-57	1687-1693	living	_	_	_	_
13-58	1694-1699	there	_	_	_	_
13-59	1700-1703	and	_	_	_	_
13-60	1704-1713	corrected	_	_	_	_
13-61	1714-1717	for	_	_	_	_
13-62	1718-1728	purchasing	_	_	_	_
13-63	1729-1734	power	abstract	giv	_	_
13-64	1735-1740	using	_	_	_	_
13-65	1741-1742	a	object[86]	new[86]	_	_
13-66	1743-1744	“	object[86]	new[86]	_	_
13-67	1745-1751	basket	object[86]	new[86]	_	_
13-68	1752-1754	of	object[86]	new[86]	_	_
13-69	1755-1760	goods	object[86]|object	new[86]|giv	_	_
13-70	1761-1762	”	object[86]	new[86]	_	_
13-71	1763-1764	.	_	_	_	_

#Text=However , no FeLV prevalence data were available for many European countries , or the data were obtained several years ago .
14-1	1765-1772	However	_	_	_	_
14-2	1773-1774	,	_	_	_	_
14-3	1775-1777	no	abstract[90]	new[90]	coref	14-15[92_90]
14-4	1778-1782	FeLV	abstract|abstract[90]	giv|new[90]	coref	15-14
14-5	1783-1793	prevalence	abstract|abstract[90]	giv|new[90]	_	_
14-6	1794-1798	data	abstract[90]	new[90]	_	_
14-7	1799-1803	were	_	_	_	_
14-8	1804-1813	available	_	_	_	_
14-9	1814-1817	for	_	_	_	_
14-10	1818-1822	many	place[91]	giv[91]	coref	16-7[105_91]
14-11	1823-1831	European	place[91]	giv[91]	_	_
14-12	1832-1841	countries	place[91]	giv[91]	_	_
14-13	1842-1843	,	_	_	_	_
14-14	1844-1846	or	_	_	_	_
14-15	1847-1850	the	abstract[92]	giv[92]	coref	18-20[125_92]
14-16	1851-1855	data	abstract[92]	giv[92]	_	_
14-17	1856-1860	were	_	_	_	_
14-18	1861-1869	obtained	_	_	_	_
14-19	1870-1877	several	time[93]	new[93]	_	_
14-20	1878-1883	years	time[93]	new[93]	_	_
14-21	1884-1887	ago	time[93]	new[93]	_	_
14-22	1888-1889	.	_	_	_	_

#Text=The aim of the present study was to determine the current prevalence of FeLV viraemia in cats that visit a veterinary facility .
15-1	1890-1893	The	abstract[94]	new[94]	_	_
15-2	1894-1897	aim	abstract[94]	new[94]	_	_
15-3	1898-1900	of	abstract[94]	new[94]	_	_
15-4	1901-1904	the	abstract[94]|abstract[95]	new[94]|giv[95]	coref	16-2[0_95]
15-5	1905-1912	present	abstract[94]|abstract[95]	new[94]|giv[95]	_	_
15-6	1913-1918	study	abstract[94]|abstract[95]	new[94]|giv[95]	_	_
15-7	1919-1922	was	_	_	_	_
15-8	1923-1925	to	_	_	_	_
15-9	1926-1935	determine	_	_	_	_
15-10	1936-1939	the	abstract[96]	new[96]	coref	19-17[133_96]
15-11	1940-1947	current	abstract[96]	new[96]	_	_
15-12	1948-1958	prevalence	abstract[96]	new[96]	_	_
15-13	1959-1961	of	abstract[96]	new[96]	_	_
15-14	1962-1966	FeLV	abstract[96]|abstract|abstract[98]	new[96]|giv|new[98]	coref|coref|coref|coref	18-6|20-41[156_98]|18-6|20-41[156_98]
15-15	1967-1975	viraemia	abstract[96]|abstract[98]	new[96]|new[98]	_	_
15-16	1976-1978	in	abstract[96]|abstract[98]	new[96]|new[98]	_	_
15-17	1979-1983	cats	abstract[96]|abstract[98]|animal	new[96]|new[98]|giv	coref	16-5
15-18	1984-1988	that	_	_	_	_
15-19	1989-1994	visit	_	_	_	_
15-20	1995-1996	a	place[101]	new[101]	coref	17-14[110_101]
15-21	1997-2007	veterinary	person|place[101]	new|new[101]	coref	17-15
15-22	2008-2016	facility	place[101]	new[101]	_	_
15-23	2017-2018	.	_	_	_	_

#Text=The study protocol included cats from 32 European countries in the survey .
16-1	2019-2022	The	abstract[103]	new[103]	_	_
16-2	2023-2028	study	abstract|abstract[103]	giv|new[103]	_	_
16-3	2029-2037	protocol	abstract[103]	new[103]	_	_
16-4	2038-2046	included	_	_	_	_
16-5	2047-2051	cats	animal	giv	coref	17-8[108_0]
16-6	2052-2056	from	_	_	_	_
16-7	2057-2059	32	place[105]	giv[105]	coref	19-24[136_105]
16-8	2060-2068	European	place[105]	giv[105]	_	_
16-9	2069-2078	countries	place[105]	giv[105]	_	_
16-10	2079-2081	in	place[105]	giv[105]	_	_
16-11	2082-2085	the	place[105]|abstract[106]	giv[105]|new[106]	_	_
16-12	2086-2092	survey	place[105]|abstract[106]	giv[105]|new[106]	_	_
16-13	2093-2094	.	_	_	_	_

#Text=In order to avoid any preselection of the cats ( apart from visiting a veterinary facility ) , 10 animals arriving consecutively at each facility were tested independently of the reason for the veterinary appointment .
17-1	2095-2097	In	_	_	_	_
17-2	2098-2103	order	_	_	_	_
17-3	2104-2106	to	_	_	_	_
17-4	2107-2112	avoid	_	_	_	_
17-5	2113-2116	any	abstract[107]	new[107]	_	_
17-6	2117-2129	preselection	abstract[107]	new[107]	_	_
17-7	2130-2132	of	abstract[107]	new[107]	_	_
17-8	2133-2136	the	abstract[107]|animal[108]	new[107]|giv[108]	_	_
17-9	2137-2141	cats	abstract[107]|animal[108]	new[107]|giv[108]	_	_
17-10	2142-2143	(	_	_	_	_
17-11	2144-2149	apart	_	_	_	_
17-12	2150-2154	from	_	_	_	_
17-13	2155-2163	visiting	_	_	_	_
17-14	2164-2165	a	place[110]	giv[110]	coref	17-24[112_110]
17-15	2166-2176	veterinary	person|place[110]	giv|giv[110]	coref	17-34
17-16	2177-2185	facility	place[110]	giv[110]	_	_
17-17	2186-2187	)	_	_	_	_
17-18	2188-2189	,	_	_	_	_
17-19	2190-2192	10	animal[111]	new[111]	_	_
17-20	2193-2200	animals	animal[111]	new[111]	_	_
17-21	2201-2209	arriving	_	_	_	_
17-22	2210-2223	consecutively	_	_	_	_
17-23	2224-2226	at	_	_	_	_
17-24	2227-2231	each	place[112]	giv[112]	_	_
17-25	2232-2240	facility	place[112]	giv[112]	_	_
17-26	2241-2245	were	_	_	_	_
17-27	2246-2252	tested	_	_	_	_
17-28	2253-2266	independently	_	_	_	_
17-29	2267-2269	of	_	_	_	_
17-30	2270-2273	the	abstract[113]	new[113]	_	_
17-31	2274-2280	reason	abstract[113]	new[113]	_	_
17-32	2281-2284	for	abstract[113]	new[113]	_	_
17-33	2285-2288	the	abstract[113]|event[115]	new[113]|new[115]	_	_
17-34	2289-2299	veterinary	abstract[113]|person|event[115]	new[113]|giv|new[115]	_	_
17-35	2300-2311	appointment	abstract[113]|event[115]	new[113]|new[115]	_	_
17-36	2312-2313	.	_	_	_	_

#Text=Risk and protective factors for FeLV infection were determined using the demographic , husbandry , clinical as well as FeLV vaccination history data from each cat .
18-1	2314-2318	Risk	abstract	new	_	_
18-2	2319-2322	and	_	_	_	_
18-3	2323-2333	protective	abstract[117]	new[117]	_	_
18-4	2334-2341	factors	abstract[117]	new[117]	_	_
18-5	2342-2345	for	abstract[117]	new[117]	_	_
18-6	2346-2350	FeLV	abstract[117]|animal|abstract[119]	new[117]|giv|giv[119]	coref|coref	18-20|18-20
18-7	2351-2360	infection	abstract[117]|abstract[119]	new[117]|giv[119]	_	_
18-8	2361-2365	were	_	_	_	_
18-9	2366-2376	determined	_	_	_	_
18-10	2377-2382	using	_	_	_	_
18-11	2383-2386	the	abstract[120]	new[120]	_	_
18-12	2387-2398	demographic	abstract[120]	new[120]	_	_
18-13	2399-2400	,	_	_	_	_
18-14	2401-2410	husbandry	abstract	new	_	_
18-15	2411-2412	,	_	_	_	_
18-16	2413-2421	clinical	_	_	_	_
18-17	2422-2424	as	_	_	_	_
18-18	2425-2429	well	_	_	_	_
18-19	2430-2432	as	_	_	_	_
18-20	2433-2437	FeLV	animal|abstract[125]	giv|giv[125]	coref|coref|coref|coref	19-4[128_125]|19-18|19-4[128_125]|19-18
18-21	2438-2449	vaccination	abstract|abstract[125]	new|giv[125]	coref	19-40
18-22	2450-2457	history	abstract|abstract[125]	new|giv[125]	_	_
18-23	2458-2462	data	abstract[125]	giv[125]	_	_
18-24	2463-2467	from	abstract[125]	giv[125]	_	_
18-25	2468-2472	each	abstract[125]|animal[126]	giv[125]|giv[126]	_	_
18-26	2473-2476	cat	abstract[125]|animal[126]	giv[125]|giv[126]	_	_
18-27	2477-2478	.	_	_	_	_

#Text=Furthermore , using our data , we tested the recently postulated hypothesis of a correlation between the FeLV prevalence and the GDP in European countries , and extended the analysis to test also for a potential correlation with FeLV vaccination rates .
19-1	2479-2490	Furthermore	_	_	_	_
19-2	2491-2492	,	_	_	_	_
19-3	2493-2498	using	_	_	_	_
19-4	2499-2502	our	person|abstract[128]	acc|giv[128]	ana|ana	19-7|19-7
19-5	2503-2507	data	abstract[128]	giv[128]	_	_
19-6	2508-2509	,	_	_	_	_
19-7	2510-2512	we	person	giv	_	_
19-8	2513-2519	tested	_	_	_	_
19-9	2520-2523	the	abstract[130]	new[130]	_	_
19-10	2524-2532	recently	abstract[130]	new[130]	_	_
19-11	2533-2543	postulated	abstract[130]	new[130]	_	_
19-12	2544-2554	hypothesis	abstract[130]	new[130]	_	_
19-13	2555-2557	of	abstract[130]	new[130]	_	_
19-14	2558-2559	a	abstract[130]|abstract[131]	new[130]|new[131]	coref	19-35[138_131]
19-15	2560-2571	correlation	abstract[130]|abstract[131]	new[130]|new[131]	_	_
19-16	2572-2579	between	abstract[130]|abstract[131]	new[130]|new[131]	_	_
19-17	2580-2583	the	abstract[130]|abstract[131]|abstract[133]|abstract[134]	new[130]|new[131]|giv[133]|giv[134]	_	_
19-18	2584-2588	FeLV	abstract[130]|abstract[131]|abstract|abstract[133]|abstract[134]	new[130]|new[131]|giv|giv[133]|giv[134]	coref	19-39
19-19	2589-2599	prevalence	abstract[130]|abstract[131]|abstract[133]|abstract[134]	new[130]|new[131]|giv[133]|giv[134]	_	_
19-20	2600-2603	and	abstract[130]|abstract[131]|abstract[134]	new[130]|new[131]|giv[134]	_	_
19-21	2604-2607	the	abstract[130]|abstract[131]|abstract[134]|abstract[135]	new[130]|new[131]|giv[134]|giv[135]	_	_
19-22	2608-2611	GDP	abstract[130]|abstract[131]|abstract[134]|abstract[135]	new[130]|new[131]|giv[134]|giv[135]	_	_
19-23	2612-2614	in	abstract[130]|abstract[131]|abstract[134]|abstract[135]	new[130]|new[131]|giv[134]|giv[135]	_	_
19-24	2615-2623	European	abstract[130]|abstract[131]|abstract[134]|abstract[135]|place[136]	new[130]|new[131]|giv[134]|giv[135]|giv[136]	_	_
19-25	2624-2633	countries	abstract[130]|abstract[131]|abstract[134]|abstract[135]|place[136]	new[130]|new[131]|giv[134]|giv[135]|giv[136]	_	_
19-26	2634-2635	,	_	_	_	_
19-27	2636-2639	and	_	_	_	_
19-28	2640-2648	extended	_	_	_	_
19-29	2649-2652	the	abstract[137]	new[137]	_	_
19-30	2653-2661	analysis	abstract[137]	new[137]	_	_
19-31	2662-2664	to	_	_	_	_
19-32	2665-2669	test	_	_	_	_
19-33	2670-2674	also	_	_	_	_
19-34	2675-2678	for	_	_	_	_
19-35	2679-2680	a	abstract[138]	giv[138]	_	_
19-36	2681-2690	potential	abstract[138]	giv[138]	_	_
19-37	2691-2702	correlation	abstract[138]	giv[138]	_	_
19-38	2703-2707	with	abstract[138]	giv[138]	_	_
19-39	2708-2712	FeLV	abstract[138]|abstract|abstract[141]	giv[138]|giv|new[141]	coref|coref	20-41|20-41
19-40	2713-2724	vaccination	abstract[138]|abstract|abstract[141]	giv[138]|giv|new[141]	_	_
19-41	2725-2730	rates	abstract[138]|abstract[141]	giv[138]|new[141]	_	_
19-42	2731-2732	.	_	_	_	_

#Text=For minimally invasive sample collection and to avoid bias by requesting blood collection , saliva swabs were collected and analysed by RT-qPCR ; the detection of viral RNA by RT-qPCR in saliva was shown to be an excellent measure of FeLV viraemia .
20-1	2733-2736	For	_	_	_	_
20-2	2737-2746	minimally	abstract[143]	new[143]	coref	20-12[146_143]
20-3	2747-2755	invasive	abstract[143]	new[143]	_	_
20-4	2756-2762	sample	object|abstract[143]	new|new[143]	_	_
20-5	2763-2773	collection	abstract[143]	new[143]	_	_
20-6	2774-2777	and	_	_	_	_
20-7	2778-2780	to	_	_	_	_
20-8	2781-2786	avoid	_	_	_	_
20-9	2787-2791	bias	abstract	new	_	_
20-10	2792-2794	by	_	_	_	_
20-11	2795-2805	requesting	_	_	_	_
20-12	2806-2811	blood	substance|abstract[146]	new|giv[146]	_	_
20-13	2812-2822	collection	abstract[146]	giv[146]	_	_
20-14	2823-2824	,	_	_	_	_
20-15	2825-2831	saliva	abstract|object[148]	new|new[148]	coref|coref	20-32|20-32
20-16	2832-2837	swabs	object[148]	new[148]	_	_
20-17	2838-2842	were	_	_	_	_
20-18	2843-2852	collected	_	_	_	_
20-19	2853-2856	and	_	_	_	_
20-20	2857-2865	analysed	_	_	_	_
20-21	2866-2868	by	_	_	_	_
20-22	2869-2876	RT-qPCR	object	new	coref	20-30[152_0]
20-23	2877-2878	;	_	_	_	_
20-24	2879-2882	the	abstract[150]	new[150]	_	_
20-25	2883-2892	detection	abstract[150]	new[150]	_	_
20-26	2893-2895	of	abstract[150]	new[150]	_	_
20-27	2896-2901	viral	abstract[150]|substance[151]	new[150]|new[151]	_	_
20-28	2902-2905	RNA	abstract[150]|substance[151]	new[150]|new[151]	_	_
20-29	2906-2908	by	abstract[150]	new[150]	_	_
20-30	2909-2916	RT-qPCR	abstract[150]|object[152]	new[150]|giv[152]	_	_
20-31	2917-2919	in	abstract[150]|object[152]	new[150]|giv[152]	_	_
20-32	2920-2926	saliva	abstract[150]|object[152]|substance	new[150]|giv[152]|giv	_	_
20-33	2927-2930	was	_	_	_	_
20-34	2931-2936	shown	_	_	_	_
20-35	2937-2939	to	_	_	_	_
20-36	2940-2942	be	_	_	_	_
20-37	2943-2945	an	abstract[154]	new[154]	_	_
20-38	2946-2955	excellent	abstract[154]	new[154]	_	_
20-39	2956-2963	measure	abstract[154]	new[154]	_	_
20-40	2964-2966	of	abstract[154]	new[154]	_	_
20-41	2967-2971	FeLV	abstract[154]|abstract|abstract[156]	new[154]|giv|giv[156]	_	_
20-42	2972-2980	viraemia	abstract[154]|abstract[156]	new[154]|giv[156]	_	_
20-43	2981-2982	.	_	_	_	_
